Antibe Therapeutics Inc (ATE.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
| 09-2017 | 06-2017 | 03-2017 | 12-2016 | 09-2016 | |
| Sales | 1,795 | 2,271 | 2,276 | 1,961 | 2,187 |
| Cost of Goods | 1,136 | 1,301 | 1,257 | 1,110 | 1,281 |
| Gross Profit | 660 | 970 | 1,019 | 851 | 906 |
| Operating Expenses | 2,396 | 2,628 | 2,910 | 2,262 | 1,886 |
| Operating Income | -1,736 | -1,658 | -1,891 | -1,411 | -980 |
| Interest Expense | 231 | 230 | 216 | 219 | 203 |
| Other Income | 105 | 69 | 43 | -65 | -17 |
| Pre-tax Income | -1,863 | -1,819 | -2,064 | -1,696 | -1,199 |
| Income Tax | -176 | -87 | -444 | 161 | -37 |
| Net Income Continuous | -1,688 | -1,733 | -1,620 | -1,857 | -1,162 |
| Net Income | $-1,688 | $-1,733 | $-1,620 | $-1,857 | $-1,162 |
| EPS Basic Total Ops | -0.10 | -0.20 | -0.20 | -0.20 | -0.10 |
| EPS Basic Continuous Ops | -0.10 | -0.20 | -0.20 | -0.20 | -0.10 |
| EPS Diluted Total Ops | -0.10 | -0.20 | -0.20 | -0.20 | -0.10 |
| EPS Diluted Continuous Ops | -0.10 | -0.20 | -0.20 | -0.20 | -0.10 |
| EBITDA(a) | $-1,540 | $-1,498 | $-1,759 | $-1,383 | $-911 |